Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling.

ABSTRACT: Risk stratification of acute myeloid leukemia (AML) patients needs improvement. Several AML risk classification models based on somatic mutations or gene-expression profiling have been proposed. However, systematic and independent validation of these models is required for future clinical implementation. We performed whole-transcriptome RNA-sequencing and panel-based deep DNA sequencing of 23 genes in 274 intensively treated AML patients (Clinseq-AML). We also utilized the The Cancer Genome Atlas (TCGA)-AML study (N=142) as a second validation cohort. We evaluated six previously proposed molecular-based models for AML risk stratification and two revised risk classification systems combining molecular- and clinical data. Risk groups stratified by five out of six models showed different over

SUBMITTER: Wang M 

PROVIDER: S-EPMC5629364 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature